Analysis & ranking
BIOMEDICAL RESEARCH INTELLIGENCE REPORT
Run ID: 2026-05-27-TRIAGE-001 | 16 Articles | Phase 2–4 Analysis
PHASE 2 — Evidence and Impact Analysis
Article 1 — NeoCircle: ctDNA dynamics predict survival in early breast cancer
PMID: 42192203 | 🔴 EARLY_CANCER_DETECTION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | SV-based personalized ctDNA outperforming pCR as a prognostic anchor in early breast cancer is a meaningful step beyond prior ctDNA work; 13.8-month MRD lead time is a specifically quantified, clinically actionable advance |
| Clinical Relevance | 8 | Directly challenges the primacy of pCR; post-op ctDNA could reshape adjuvant escalation decisions in a high-volume clinical setting |
| Population Reach | 8 | Early breast cancer is one of the highest-incidence cancers globally (~2.3M new cases/year); neoadjuvant therapy is standard-of-care for many subtypes |
| Implementation Speed | 6 | Personalized SV-panel design (SAGA Diagnostics) requires biopsy upfront, lab infrastructure, and regulatory clearance; commercial pathway exists but is not yet routine; 2–5 year realistic timeline |
| Evidence Strength | 7 | Prospective cohort design (NCT02306096 substudy), peer-reviewed EMBO Mol Med, PMC full text, ultrasensitive dPCR methodology; limited by n=136 and single-institution subpopulation; COI (SAGA Diagnostics co-founders) warrants note |
Key quantitative result: End-NAT ctDNA positivity rate 21.4%; NAT ctDNA-non-response 13.1%; post-op ctDNA lead time to relapse 13.8 months; both independently predicted recurrence and death beyond pCR.
External validation: Single-arm substudy of SCAN-B; no independent external replication yet reported, though methodology extends prior SCAN-B work.
Main limitation: n=136 from a single Scandinavian center (Lund University/Skåne); SAGA Diagnostics COI; results need prospective multicenter replication before clinical implementation.
Equity implications: Personalized SV-panel ctDNA is currently expensive and lab-intensive; likely to benefit well-resourced healthcare systems first. Populations with limited genomics infrastructure (LMICs, rural settings) may be underserved. Patients who cannot access neoadjuvant therapy at all are excluded from benefit.
Evidence Maturity: Confirmed Validated — prospective cohort with strong methodology; not yet practice-changing pending multicenter replication.
Article 2 — Compound EGFR PACC mutations: second-gen TKI superiority in NSCLC
PMID: 42191070 | 🟠 NOVEL_TREATMENT
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Establishes that compound PACC mutations (66.2% in-cis) retain second-gen TKI superiority — directly counters a plausible assumption that compounding would alter drug sensitivity; clinically underrecognized mutation class |
| Clinical Relevance | 9 | Immediately actionable treatment selection guidance: patients with compound PACC mutations currently risk receiving osimertinib (third-gen) when afatinib/dacomitinib (second-gen) is superior; reclassification changes treatment decisions today |
| Population Reach | 7 | PACC mutations in 9% of EGFR-mutant NSCLC; EGFR-mutant NSCLC |
| Implementation Speed | 8 | cfDNA/NGS already routine in NSCLC; reclassification framework could be implemented in molecular tumor boards immediately; requires only updated reporting and guideline awareness |
| Evidence Strength | 6 | Large n (15,851 cfDNA samples; 1,542 clinical patients) provides statistical robustness; however, retrospective/real-world design with in vitro validation only; no prospective RCT; abstract-only access caps confidence; design quality scored 1/2 in triage |
Key quantitative result: PACC mutations in 9% of EGFR-mutant NSCLC; 66.2% occur as compound in-cis; compound PACC mutations show equivalent second-gen TKI superiority to single PACC mutations across MDACC + Guardant cohorts (n=1,542 clinical patients).
External validation: Cross-validated across two independent real-world cohorts (MDACC institutional + Guardant Health commercial cfDNA registry); in vitro mechanistic confirmation included.
Main limitation: Retrospective design; no prospective randomized comparison of second- vs third-gen TKI in PACC-specific patients; abstract-only reviewed; PFS/OS data from real-world cohorts subject to confounding.
Equity implications: cfDNA comprehensive genomic profiling (Guardant) is not universally available or reimbursed; patients without access to broad-panel NGS may be systematically misclassified. Benefits accrue primarily to patients at well-resourced academic or large community centers.
Evidence Maturity: Confirmed Validated with important caveat — high clinical actionability but retrospective; prospective confirmation warranted before becoming hard guideline.
Article 3 — PAPILLON China subgroup: amivantamab + chemo in EGFR exon 20 insertion NSCLC
PMID: 42192224 | 🟠 NOVEL_TREATMENT
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Confirmatory subgroup of a published phase 3 RCT; no new mechanism or treatment strategy; value is population-specific generalizability confirmation, not scientific discovery |
| Clinical Relevance | 8 | EGFR exon 20 insertion NSCLC has historically been resistant to standard TKIs; amivantamab approval was a breakthrough; Chinese patient validation is directly clinically relevant for a major patient population and regulatory decision-making |
| Population Reach | 6 | Exon 20 insertions represent |
| Implementation Speed | 9 | Amivantamab already approved (FDA, EMA); Chinese regulatory pathway is the primary remaining step; data directly supports NMPA submission; treatment is "in practice" in most markets |
| Evidence Strength | 7 | Phase 3 RCT pedigree (NCT04538664) with prespecified subgroup; HR 0.47 is clinically meaningful; however n=87 is not independently powered; manufacturer COI (J&J authors); results are consistent with but nested within global data |
Key quantitative result: mPFS 12.3 vs 6.7 months (HR 0.47, 95% CI 0.26–0.85, p=0.0109); ORR 71.8% vs 48.9%.
External validation: Internally consistent with global PAPILLON population — this is the key validation message. Not independently replicated outside PAPILLON framework.
Main limitation: n=87 subgroup not independently powered; J&J author COI; cannot exclude ethnic/geographic confounders as explanatory vs treatment effect alone.
Equity implications: This study specifically benefits Chinese patients — a population often underrepresented in Western-led trials. The result supports regulatory equity (ensuring NMPA approval) and addresses a historical access gap. Broader LMICs with high NSCLC burden remain underserved.
Evidence Maturity: Confirmed Validated — subgroup-level validation within a practice-changing RCT.
Article 4 — EASL-AASLD Delphi consensus: surrogate endpoints in PBC
PMID: 42191456 | 🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Not a discovery paper; novel in scope of consensus and operationalization of regulatory pathway, but consensus statements are codifications of existing knowledge |
| Clinical Relevance | 8 | Directly enables full approval of 3 conditionally-approved second-line PBC therapies; for a rare disease with no curative options and progressive liver fibrosis, this is high-stakes regulatory science |
| Population Reach | 4 | PBC prevalence ~40/100,000 (predominantly women); high unmet need within this rare population; relative to the PBC clinical community, reach is substantial |
| Implementation Speed | 8 | Consensus is published and operational; adoption by regulatory agencies (EMA, FDA, PMDA) and ongoing trial sponsors could begin immediately; J Hepatology publication maximizes awareness |
| Evidence Strength | 7 | Modified Delphi with 62 panelists, 88% response rate, 3 voting rounds, multi-stakeholder (clinicians, regulators, industry, patients); well-established methodology for consensus science; abstract-only reviewed slightly limits scoring |
Key quantitative result: 16 consensus statements, 42 recommendations, ≥80% agreement threshold; >90% alignment with existing international guidelines.
External validation: Explicitly aligned with ESMO, ELBS, ISLB, and AMP-CAP existing frameworks — strong convergent validity.
Main limitation: Consensus statements do not constitute clinical trial evidence; uptake depends on regulatory agency response; abstract-only reviewed.
Equity implications: PBC disproportionately affects women (>90%) and is often diagnosed late; faster regulatory approvals directly benefit this group. Global equity concern: access to second-line PBC therapies remains limited in LMICs regardless of regulatory consensus in Western jurisdictions.
Evidence Maturity: Confirmed Validated — operationally ready consensus, near-term implementable.
Article 5 — Optimized PET/CT response assessment in extranodal NK/T-cell lymphoma
PMID: 42191947 | ⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Novel IPN criteria (nasal mucosal uptake threshold) for a specific lymphoma subtype where standard Lugano criteria are known to underperform; methodologically creative for a rare disease |
| Clinical Relevance | 7 | ENKTL is aggressive with poor outcomes; better risk stratification enabling earlier treatment intensification has meaningful survival implications |
| Population Reach | 4 | ENKTL is rare globally (higher incidence in East Asia); limited absolute population size but high unmet need within this rare, typically fatal disease |
| Implementation Speed | 5 | Requires prospective validation and radiology/nuclear medicine protocol standardization; multicenter reproducibility unclear; 3–5 years realistic |
| Evidence Strength | 6 | Multicenter retrospective (n=259, two high-volume Chinese centers); C-index reported; abstract-only limits full assessment of methodology |
Key quantitative result: IPN criteria achieved highest C-index for PFS and OS vs Lugano; CR reclassification by NPU/IPN predicted improved outcomes.
Main limitation: Retrospective; single-country (China); requires external prospective validation in non-Asian ENKTL populations.
Equity implications: ENKTL disproportionately affects East Asian and Latin American patients — study population is representative of highest-incidence group but requires validation in other regions.
Evidence Maturity: Confirmed Validated (within retrospective bounds); prospective international validation needed.
Article 6 — Immunotherapies in multiple myeloma: CAR-T and bispecific antibodies
PMID: 42190708 | ⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Narrative review of established FDA-approved agents; clinical synthesis value but no new discovery |
| Clinical Relevance | 8 | All 6 FDA-approved CAR-T/BsAb agents covered with frontline development data; strong practical guide for oncologists managing MM |
| Population Reach | 6 | Multiple myeloma ~36,000 new US cases/year; globally ~175,000/year; major hematologic malignancy |
| Implementation Speed | 7 | Agents are already approved; review guides immediate clinical practice decisions on sequencing and toxicity management |
| Evidence Strength | 5 | Narrative review from MSK Myeloma Service — authoritative source, curated coverage, but not a systematic review or meta-analysis; abstract-only |
Main limitation: Narrative review subject to selection bias; no formal evidence synthesis methodology.
Equity implications: CAR-T and bispecific antibodies have extreme cost and access barriers; review does not address equity in access. Patient populations outside major academic centers are significantly underserved.
Evidence Maturity: Confirmed Validated — synthesis of established evidence.
Article 7 — PCR-based MRD in pediatric KMT2A-rearranged AML
PMID: 42190411 | ⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | PCR-MRD in AML is established; novelty is KMT2A-specific serial timepoint analysis (EOI1, EOI2, EOC1) and allo-HSCT decision guidance in a pediatric high-risk subtype |
| Clinical Relevance | 7 | Directly informs allo-HSCT CR1 decision in a high-risk pediatric AML subtype where relapse is often fatal |
| Population Reach | 4 | KMT2A-r AML is rare; ~5–10% of pediatric AML cases; global pediatric AML incidence ~7–8/million children/year |
| Implementation Speed | 6 | PCR-MRD is technically available at major centers; requires protocol integration into trial frameworks; small n caps adoption confidence |
| Evidence Strength | 5 | n=46 limits statistical power despite prospective registration; retrospective data collection; abstract-only; single-center Beijing |
Main limitation: Very small n=46; single Chinese center; retrospective data despite registration; needs multicenter pediatric validation.
Equity implications: Pediatric KMT2A-r AML disproportionately impacts young children; allo-HSCT decision-making benefits from better MRD guidance but transplant access is highly inequitable globally.
Evidence Maturity: Confirmed Validated within small-cohort bounds; requires multicenter replication.
Article 8 — cfDNA ERBB2 copy number predicts prognosis in HER2+ gastric cancer
PMID: 42192045 | ⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Dynamic ΔCN (longitudinal change) superior to baseline ERBB2 CN as prognostic marker; shifts paradigm from static to dynamic liquid biopsy monitoring |
| Clinical Relevance | 6 | Provides on-treatment prognostic signal in HER2+ gastric cancer; could guide early switch decisions but not yet validated as a treatment-selection or intervention trigger |
| Population Reach | 5 | HER2+ gastric cancer ~15–20% of gastric cancers; gastric cancer ~1 million new cases/year globally; meaningful absolute numbers |
| Implementation Speed | 5 | ddPCR ERBB2 CN monitoring is technically feasible; requires prospective validation as decision tool before clinical adoption |
| Evidence Strength | 6 | Pre-specified correlative analysis within phase II trial (clean design); ddPCR robust methodology; multivariable analysis; limited by n=55 and abstract-only |
Main limitation: n=55; single phase II trial; no prospective decision-making validation; Japan-only cohort.
Equity implications: HER2-targeted therapies are not universally accessible; liquid biopsy monitoring would further concentrate benefit in well-resourced settings.
Evidence Maturity: Confirmed Validated (within small trial-embedded scope).
Article 9 — AI-enhanced POCUS by GPs for carotid plaque detection
PMID: 42191361 | 🟢 NEAR_TERM_IMPLEMENTABLE
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | GP-performed AI-POCUS for carotid atherosclerosis is not entirely new but systematic training + real-world primary care validation is meaningfully novel |
| Clinical Relevance | 7 | Moves specialist-level vascular imaging to primary care; strong diagnostic performance (sens 87%, spec 91%, κ=0.78) in the target population |
| Population Reach | 8 | Cardiovascular disease is the leading cause of death globally; elderly high-risk populations underscreened in primary care worldwide |
| Implementation Speed | 6 | Requires AI-POCUS device procurement, structured GP training program, and workflow integration; feasible in 2–5 years in resource-adequate systems |
| Evidence Strength | 6 | Prospective diagnostic accuracy design; n=169; single-center Shanghai; abstract-only; generalizability to non-Chinese primary care settings uncertain |
Main limitation: Single center (Shanghai); abstract-only; n=169; training protocol may not be directly exportable; no long-term outcome data.
Equity implications: Primary care implementation could narrow the specialist-access gap for underserved elderly populations. However, AI-POCUS device cost may itself create a new access barrier in low-income settings.
Evidence Maturity: Confirmed Validated within single-center bounds.
Article 10 — Older women with metastatic TNBC: ESME national cohort
PMID: 42190521 | 🟡 UNDERSERVED_POPULATION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Confirms prior smaller observations; novelty is the national-scale ESME database and direct age comparison with survival equipoise finding |
| Clinical Relevance | 7 | Comparable OS despite treatment disparities is a strong argument for offering older mTNBC patients full treatment consideration; practice-relevant finding |
| Population Reach | 6 | TNBC ~15% of breast cancer; ~350,000 TNBC cases/year globally; older women (≥70) are a systematically excluded subgroup |
| Implementation Speed | 7 | No new technology required; finding argues for immediate inclusion of older women in clinical trials and consideration for standard therapies |
| Evidence Strength | 7 | Large national real-world cohort (n=4,246); UNICANCER ESME database is well-validated; retrospective limitation; abstract-only |
Main limitation: Retrospective; residual confounding (older patients may have been selected for treatment by performance status); OS comparison doesn't isolate treatment effect.
Equity implications: Directly addresses systematic underrepresentation and under-treatment of older women in oncology — one of the clearest equity signals in this batch. Argues for trial inclusion mandates for patients ≥70.
Evidence Maturity: Confirmed Validated.
Article 11 — TP53/KRAS co-mutations in biliary tract cancer and ICI benefit
PMID: 42190397 | ⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | TP53/KRAS double-mutant as a negative predictive biomarker for ICI benefit in BTC is a novel hypothesis with mechanistic plausibility; large genomic database |
| Clinical Relevance | 6 | Hypothesis-generating; treatment interaction not statistically significant (p=0.1655); not yet actionable but shapes future trial design |
| Population Reach | 5 | BTC ~210,000 new cases/year globally; ICI-treated BTC is growing but genomic subgrouping still research-stage |
| Implementation Speed | 4 | Requires prospective biomarker-stratified trial; 5–10 years to clinical adoption if validated |
| Evidence Strength | 6 | Large national C-CAT database (n=1,875); population-level genomic validity; retrospective; treatment interaction non-significant; abstract-only |
Main limitation: Non-significant treatment interaction (p=0.1655); retrospective; results are hypothesis-generating only; abstract-only reviewed.
Evidence Maturity: Revised to Exploratory — correctly classified in triage; non-significant primary interaction prevents Validated designation.
Article 12 — SGLT2 inhibitors reduce epicardial adipose tissue: meta-analysis
PMID: 42191874 | ⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | EAT reduction as a specific mechanistic pathway for SGLT2i cardiovascular benefit is a meaningful biological insight; multimodality consistency strengthens signal |
| Clinical Relevance | 6 | Mechanistic explanation for known cardiovascular benefits; does not yet change prescribing but enriches rationale for SGLT2i in high-cardiac-risk patients |
| Population Reach | 8 | SGLT2i are prescribed globally for T2D and heart failure; hundreds of millions at-risk patients |
| Implementation Speed | 7 | SGLT2i already in widespread use; EAT measurement is becoming routine in cardiac imaging; finding informs monitoring but doesn't require new drugs |
| Evidence Strength | 5 | PROSPERO-registered meta-analysis; 11 studies but only n=284 patients total — critically underpowered for subgroup analysis; multimodality consistency is a strength; abstract-only |
Main limitation: Small aggregate n=284 across 11 studies; subgroup drug comparisons underpowered; abstract-only; publication bias possible.
Evidence Maturity: Confirmed Validated (meta-analytic signal consistent) but underpowered for definitive mechanistic claims.
Article 13 — Latin American CSVD burden in aging and dementia
PMID: 42192214 | 🟡 UNDERSERVED_POPULATION
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | First large-scale Latin American CSVD-dementia cohort; fills a genuine evidence gap in an underrepresented population |
| Clinical Relevance | 6 | Cross-sectional design limits causal inference; findings inform prevention priorities but don't change treatment immediately |
| Population Reach | 7 | Latin America has ~650 million people; rapidly aging population with high cardiometabolic risk burden; dementia incidence rising faster than in Western populations |
| Implementation Speed | 5 | Findings support immediate public health messaging (blood pressure control, smoking cessation) but require longitudinal follow-up for intervention trials |
| Evidence Strength | 6 | Large n=1,675; multicenter 6-country; cross-sectional design limits causal inference; abstract-only |
Main limitation: Cross-sectional; cannot establish temporality of CSVD risk factor relationships; no longitudinal follow-up yet.
Equity implications: Directly addresses one of the largest underserved populations in dementia research. Latin American populations have distinct cardiometabolic risk profiles (higher obesity, diabetes, hypertension rates) that affect dementia risk differently than European cohorts.
Evidence Maturity: Confirmed Validated (descriptive/epidemiological scope).
Article 14 — Synaptic biomarkers in Alzheimer's disease: systematic review
PMID: 42192211 | ⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Comprehensive systematic landscape of non-amyloid/tau synaptic biomarkers; blood-based SNAP-25 and GAP-43 are emerging as translatable markers |
| Clinical Relevance | 6 | Primarily useful for trial enrichment and research protocol design; not yet standard clinical diagnostics |
| Population Reach | 8 | AD affects ~55 million globally; any improvement in early/accurate diagnosis benefits enormous numbers |
| Implementation Speed | 5 | Blood-based synaptic biomarkers (SNAP-25, GAP-43) have some commercial assay development underway but not yet widely clinically deployed; 3–7 years |
| Evidence Strength | 7 | Meta-analysis of 65 cohorts; systematic methodology; Alzheimer's & Dementia flagship; sample size not reported for aggregate; abstract-only |
Main limitation: Abstract-only; aggregate sample size not reported; heterogeneity across 65 cohorts likely substantial; most markers still require CSF (invasive).
Evidence Maturity: Confirmed Validated — strong meta-analytic synthesis of emerging biomarker landscape.
Article 15 — French Delphi consensus on ctDNA technical standardization
PMID: 42190398 | ⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Technical standardization consensus; operationally important but not scientifically novel |
| Clinical Relevance | 6 | Reduces inter-laboratory variability that currently limits ctDNA clinical deployment; enabling infrastructure for ctDNA adoption |
| Population Reach | 7 | ctDNA testing is expanding across all cancer types; standardization benefits all patients receiving liquid biopsy-guided oncology care |
| Implementation Speed | 7 | Consensus is published; platforms can adopt recommendations immediately; European harmonization process already initiated |
| Evidence Strength | 6 | 39 platforms, 71% response rate, 3-round Delphi; robust methodology for consensus science; abstract-only |
Main limitation: Consensus ≠ evidence; adoption depends on voluntary platform compliance; limited to French/European context.
Evidence Maturity: Confirmed Validated — operational consensus framework.
Article 16 — Trace elements, dietary patterns, and biological aging
PMID: 42191913 | ⬜ STANDARD
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Selenium as dominant trace element contributor to biological aging via BKMR mixture modeling; dietary mediation pathway is a testable novel hypothesis |
| Clinical Relevance | 4 | Cross-sectional; no causal evidence; cannot recommend selenium supplementation from this data alone |
| Population Reach | 7 | Dietary patterns affect all older adults; selenium is widely available; public health relevance is high if causal relationship confirmed |
| Implementation Speed | 3 | Cross-sectional design requires longitudinal replication before any dietary guidance change; 5–10+ years |
| Evidence Strength | 4 | Cross-sectional; n=2,627 is adequate for association study; BKMR modeling is appropriate but causal inference is absent; abstract-only; single Chinese cohort |
Main limitation: Cross-sectional design — cannot establish causality; single Chinese cohort; reverse causality plausible (healthier aging → better nutrition); abstract-only.
Evidence Maturity: Confirmed Exploratory.
PHASE 3 — Ranking
Conflict Summary
No direct conflicts between articles. Articles 2 and 3 address different EGFR mutations and are complementary rather than conflicting. Articles 1, 2, and 8 address ctDNA/cfDNA in different tumor types with consistent directional findings, reinforcing the clinical utility of liquid biopsy monitoring. Articles 13 and 14 both address dementia biomarkers from complementary angles (vascular vs synaptic) without contradiction.
Composite Impact Score Table
| Rank | Article | Flag | Impact Score | Clinical Rel. (30%) | Pop. Reach (25%) | Sci. Novelty (20%) | Impl. Speed (15%) | Evid. Strength (10%) | Triage Score | Study Design |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NeoCircle: ctDNA dynamics in early breast cancer (PMID 42192203) | 🔴 | 7.70 | 8 | 8 | 8 | 6 | 7 | 9 | Prospective cohort |
| 2 | Compound EGFR PACC mutations: 2nd-gen TKI (PMID 42191070) | 🟠 | 7.65 | 9 | 7 | 8 | 8 | 6 | 8 | Retrospective + in vitro |
| 3 | PAPILLON China: amivantamab in exon 20 NSCLC (PMID 42192224) | 🟠 | 7.30 | 8 | 6 | 5 | 9 | 7 | 8 | Phase 3 RCT subgroup |
| 4 | Older mTNBC: ESME national cohort (PMID 42190521) | 🟡 | 6.70 | 7 | 6 | 5 | 7 | 7 | 7 | Retrospective national cohort |
| 5 | EASL-AASLD PBC consensus: surrogate endpoints (PMID 42191456) | 🟢 | 6.65 | 8 | 4 | 5 | 8 | 7 | 8 | Modified Delphi |
| 6 | AI-POCUS by GPs: carotid plaque detection (PMID 42191361) | 🟢 | 6.65 | 7 | 8 | 6 | 6 | 6 | 7 | Diagnostic accuracy trial |
| 7 | SGLT2i reduce epicardial adipose tissue (PMID 42191874) | ⬜ | 6.55 | 6 | 8 | 6 | 7 | 5 | 7 | Systematic review/meta-analysis |
| 8 | Synaptic biomarkers in AD: meta-analysis (PMID 42192211) | ⬜ | 6.45 | 6 | 8 | 6 | 5 | 7 | 7 | Systematic review/meta-analysis |
| 9 | TP53/KRAS co-mutations in BTC and ICI (PMID 42190397) | ⬜ | 5.85 | 6 | 5 | 7 | 4 | 6 | 7 | Retrospective genomic cohort |
| 10 | ENKTL: optimized PET/CT response criteria (PMID 42191947) | ⬜ | 5.80 | 7 | 4 | 6 | 5 | 6 | 7 | Retrospective multicenter |
| 11 | Latin American CSVD in aging/dementia (PMID 42192214) | 🟡 | 5.80 | 6 | 7 | 6 | 5 | 6 | 7 | Cross-sectional multicenter |
| 12 | cfDNA ERBB2 CN in HER2+ gastric cancer (PMID 42192045) | ⬜ | 5.75 | 6 | 5 | 6 | 5 | 6 | 7 | Correlative phase II |
| 13 | MM immunotherapy review: CAR-T and BsAb (PMID 42190708) | ⬜ | 5.75 | 8 | 6 | 4 | 7 | 5 | 7 | Narrative review |
| 14 | PCR-MRD in pediatric KMT2A-r AML (PMID 42190411) | ⬜ | 5.75 | 7 | 4 | 6 | 6 | 5 | 7 | Retrospective cohort |
| 15 | French Delphi: ctDNA technical standards (PMID 42190398) | ⬜ | 5.75 | 6 | 7 | 4 | 7 | 6 | 6 | Delphi consensus |
| 16 | Trace elements, diet, and biological aging (PMID 42191913) | ⬜ | 4.60 | 4 | 7 | 6 | 3 | 4 | 6 | Cross-sectional observational |
Rank Justifications
#1 — NeoCircle (PMID 42192203): This prospective cohort study earns the top position through its combination of scientific novelty, broad population reach (early breast cancer is among the highest-volume cancer categories globally), strong evidence quality (prospective design, PMC full-text, ultrasensitive dPCR methodology), and direct clinical actionability. The 13.8-month MRD lead time before clinical relapse is the most concretely quantified clinical benefit in this batch. Its tie-breaking advantage over #2 is Evidence Strength — prospective design vs retrospective for Article 2.
Why it matters: If ctDNA-guided escalation trials using this framework show treatment benefit, a generation of early breast cancer patients could have residual disease detected and addressed nearly 14 months earlier than current imaging-based surveillance allows.
#2 — Compound EGFR PACC mutations (PMID 42191070): The highest Clinical Relevance score in the batch (9/10) reflects genuinely immediate treatment selection implications: patients with compound PACC EGFR mutations are likely being prescribed the wrong TKI in current practice. The large scale (15,851 cfDNA samples; 1,542 clinical patients) and dual-cohort validation are strengths. It ranks second rather than first because the retrospective design and abstract-only access cap Evidence Strength at 6, and it falls below the Evidence Strength threshold required for #1.
Why it matters: A 9% slice of EGFR-mutant NSCLC may be receiving suboptimal first-line treatment today. Correct molecular subclassification at diagnosis could improve outcomes for tens of thousands of patients annually with no new drugs required.
#3 — PAPILLON China subgroup (PMID 42192224): The highest Implementation Speed score (9/10) in the batch reflects the fact that amivantamab is already approved in most major markets and this data directly enables NMPA regulatory action in China — the world's largest NSCLC patient population. HR 0.47 (mPFS 12.3 vs 6.7 months) is a clinically substantial effect. Its rank is limited by low novelty (confirmatory subgroup) and the n=87 power constraint.
Why it matters: EGFR exon 20 insertion NSCLC has long been the "orphan" of EGFR-targeted therapy. This data removes the last major population-specific uncertainty for Chinese patients and accelerates access in the world's highest-burden NSCLC country.
#4 — Older mTNBC (PMID 42190521): The largest evidence-based equity signal in the batch. Comparable OS despite systematic under-treatment is a finding that could immediately change how oncologists counsel and enroll older mTNBC patients.
Why it matters: Older women with metastatic TNBC are the group most likely to be told they "might not tolerate" aggressive therapy — and this national cohort of 4,246 women suggests that assumption has been costing lives.
#5 (tied) — PBC Delphi consensus (PMID 42191456) / AI-POCUS for GPs (PMID 42191361): The PBC consensus is the single finding in this batch most likely to directly unblock a regulatory pathway within 12–18 months, making it high-impact for an underserved rare disease despite its small absolute population. The AI-POCUS study earns its co-rank through exceptional Population Reach — atherosclerosis screening in primary care is a near-universal public health need — and a genuinely scalable model.
#7–16: Remaining articles provide important incremental advances, mechanistic insights, or infrastructure contributions across their domains. The SGLT2i/EAT meta-analysis (#7) is notable for its Population Reach but limited by small aggregate n. The synaptic AD biomarker review (#8) is a valuable landscape paper for trial design. The TP53/KRAS BTC finding (#9) is the most hypothesis-generating discovery in the batch. Articles #10–16 represent solid standard additions to their respective fields.